Trial Profile
Randomized phase II study of pemetrexed and cisplatin as either induction or adjuvant chemotherapy in stage IB-II non-small cell lung cancer.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Cisplatin (Primary) ; Pemetrexed (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- 26 Jul 2012 Actual end date (July 2008) added as reported by ClinicalTrials.gov.
- 31 Aug 2009 Status changed from active, no longer recruiting to discontinued.
- 01 Aug 2009 Results have been presented at the 13th World Conference on Lung Cancer.